Imunon Balance Sheet Health

Financial Health criteria checks 4/6

Imunon has a total shareholder equity of $8.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $14.4M and $6.2M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$10.31m
EquityUS$8.19m
Total liabilitiesUS$6.20m
Total assetsUS$14.39m

Recent financial health updates

Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?

Dec 07
Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?

Is Celsion (NASDAQ:CLSN) Using Too Much Debt?

Aug 18
Is Celsion (NASDAQ:CLSN) Using Too Much Debt?

Recent updates

Celsion changes name to Imunon (IMNN)

Sep 19

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Sep 01

Celsion Q2 2022 Earnings Preview

Aug 12

Celsion adds Moderna chief commercial officer as CEO

Jul 19

Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?

Dec 07
Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?

Is Celsion (NASDAQ:CLSN) Using Too Much Debt?

Aug 18
Is Celsion (NASDAQ:CLSN) Using Too Much Debt?

Financial Position Analysis

Short Term Liabilities: IMNN's short term assets ($12.5M) exceed its short term liabilities ($5.4M).

Long Term Liabilities: IMNN's short term assets ($12.5M) exceed its long term liabilities ($757.7K).


Debt to Equity History and Analysis

Debt Level: IMNN is debt free.

Reducing Debt: IMNN has no debt compared to 5 years ago when its debt to equity ratio was 62.8%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMNN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IMNN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.6% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:10
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Imunon, Inc. is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Raymond DeaconBrean Capital
Kumaraguru RajaBrookline Capital Markets